Q-omics provides the consensus-scored OPRPN profile across patient tissues and cancer cell-line models. OPRPN expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, OPRPN is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, OPRPN RNA expression shows 6,493 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, and STAD as cancer lineages where OPRPN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OPRPN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OPRPN survival associations across molecular data types. OPRPN RNA expression shows survival associations in the most cancer types (16), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OPRPN RNA expression–survival associations across cancer types. High OPRPN expression shows unfavorable associations in BLCA, KIRP, COAD and LGG, but favorable associations in BRCA and SKCM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for OPRPN RNA expression.
This table summarizes OPRPN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OPRPN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OPRPN shows lower tumor expression in BRCA, HNSC, CHOL and PRAD and higher tumor expression in LIHC and UCEC. The BRCA box plot shows higher OPRPN RNA expression in normal versus tumor tissue (log2 FC = −3.252, t-test p < 0.001).
This table shows molecular features associated with OPRPN in patient tissues and cancer cell lines. In patient samples, OPRPN shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OPRPN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Myeloma.
